A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease

NCT02271503 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease

Interventions

DRUG: CD-LD IR
DRUG: IPX203 180 mg
DRUG: IPX203 270 mg
DRUG: Rytary 195 mg
DRUG: Rytary 145 mg

Sponsor

Impax Laboratories, LLC